Abstract Number: 1195 • 2016 ACR/ARHP Annual Meeting
Risk of Hospitalized Infection Among Patients with Sarcoidosis: A Population-Based Retrospective Cohort Study
Risk of Hospitalized Infection Among Patients With Sarcoidosis: A Population-Based Retrospective Cohort Study Background/Purpose: Increased risk of infection has been observed in several autoimmune disorders. …Abstract Number: 2625 • 2016 ACR/ARHP Annual Meeting
Safety of Multiple Retreatments with Rituximab in Real Life: Long Term Registry Data from 1984 Patients with Rheumatoid Arthritis
Background/Purpose: Data are very limited concerning the safety of multiple retreatments with rituximab (RTX) in rheumatoid arthritis in common practice. Methods: This is a multicenter…Abstract Number: 1311 • 2016 ACR/ARHP Annual Meeting
Causative Pathogens, Antibiotic Susceptibility, and Characteristics of Patients with Bacterial Septic Arthritis over Time
Background/Purpose: Management of septic arthritis remains a challenge. The emergence of methicillin-resistant Staphylococcus aureus (MRSA) strains with reduced vancomycin susceptibility and multi drug resistant (MDR)…Abstract Number: 2643 • 2016 ACR/ARHP Annual Meeting
Risk Factors of Pneumocystis Jiroveci Pneumonia (PJP) in Patients with RA and Sulfasalazine As a Possible Protective Agent
Background/Purpose: Pneumocystis jiroveci pneumonia (PJP) is a serious complication during the treatment in patients with variety of rheumatic disease. Postmarketing surveillance of infliximab and etnercept…Abstract Number: 1313 • 2016 ACR/ARHP Annual Meeting
Rheumatologic Diseases in HIV-Infected Patients in the Post-Antiretroviral Therapy Era: The County Experience
Background/Purpose: HIV infection has been associated with a plethora of rheumatologic diseases, however there are only few studies in the US analyzing the frequency of…Abstract Number: 3116 • 2016 ACR/ARHP Annual Meeting
Risk of Infections in Juvenile Idiopathic Arthritis Patients Treated with Biologic Agentsand/or Methotrexate: Results from Pharmachild Registry
Background/Purpose: Pharmachild is an international registry involving over 100 the Paediatric Rheumatology INternational Trials Organisation (PRINTO)/ the Paediatric Rheumatology European Society (PRES) centres in 38 countries. The registry was set up to evaluate long term safety and efficacy…Abstract Number: 1316 • 2016 ACR/ARHP Annual Meeting
Clinical Features and Outcomes of Prosthetic Joint Septic Arthritis: The Gender Effect
Background/Purpose: In developed countries, certain health outcomes are worse among men. For example, in the US, life expectancy for men is 5 years shorter than…Abstract Number: 1317 • 2016 ACR/ARHP Annual Meeting
Do Patients with MRSA-Positive Septic Arthritis Differ Clinically from Non-MRSA-Positive Counterparts?
Do patients with MRSA-positive septic arthritis differ clinically from non-MRSA-positive counterparts? Mary Louise Fowler3, Kevin Byrne3, Sarah B. Lieber1, Andrew Moore2, Robert H. Shmerling1, Ziv…Abstract Number: 1351 • 2016 ACR/ARHP Annual Meeting
Mortality and Prognostic Factors of Pneumocystis Pneumonia in Patients with Connective Tissue Diseases
Background/Purpose: Pneumocystis pneumonia (PCP) is one of the severe opportunistic infections in immunocompromised patients. PCP is still a leading cause of death in patients with…Abstract Number: 1502 • 2016 ACR/ARHP Annual Meeting
Vaccination Program to Prevent Hospital Admissions Due to Serious Respiratory Infections in Rheumatoid Arthritis Patients. Prosprective Study of 294 Patients
Background/Purpose: Patients with Rheumatoid Arthritis (RA) are at increased risk of infections, especially serious respiratory infections. Immunization is a recommended to reduce these complications.…Abstract Number: 1684 • 2016 ACR/ARHP Annual Meeting
Updated Results for Serious Infections in Psoriasis Patients with Psoriatic Arthritis in the Psoriasis Longitudinal Assessment and Registry Study
Background/Purpose: To describe the rates of serious infections (SI) in psoriasis (PsO) pts with psoriatic arthritis (PsA) from PSOLAR, & assess risk with biologic therapy.…Abstract Number: 1346 • 2015 ACR/ARHP Annual Meeting
The Presentation and Outcomes of Surgically Treated Septic Arthritis: the Impact of Culture Results
Background/Purpose: Clinically-suspected septic arthritis is culture-negative in 18-43% of cases. These patients are often treated surgically with associated morbidity, prolonged hospital stays and high medical…Abstract Number: 3238 • 2015 ACR/ARHP Annual Meeting
The Impact of Biologic DMARD Treatment on Sepsis and Mortality after Serious Infection
Background/Purpose: Tumor-necrosis-factor-α inhibition (TNFi) was assumed to be a relevant mechanism for the treatment of sepsis[1]. However, randomized controlled trials failed to show a survival…Abstract Number: 1349 • 2015 ACR/ARHP Annual Meeting
Clinical Characteristics and Outcomes of Septic Bursitis
Background/Purpose: Septic bursitis (SB) is a common condition that typically involves the olecranon and patellar bursae. It is unclear whether patients with SB treated surgically…Abstract Number: 1357 • 2015 ACR/ARHP Annual Meeting
Cytomegalovirus (CMV) Infections in Patients with Rheumatic Diseases: Experience of a Referral Center
Background/Purpose: CMV is a ubiquitous herpes virus associated with significant immunosuppression. Immunosuppressive treatments and ageing is well known risk factors for CMV reactivation. There are…
- « Previous Page
- 1
- …
- 25
- 26
- 27
- 28
- 29
- …
- 32
- Next Page »